DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
Study Details
LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
Conditions: Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
Study ID:
ONC24025 (Firefly-2)
Study Description
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.
Eligibility Requirements
Inclusion Criteria
- Less than 25 years of age with LGG with known activating RAF alteration.
- Histopathologic diagnosis of glioma or glioneuronal tumor.
- At least one measurable lesion as defined by RANO criteria.
- Meet indication for first-line systemic therapy.
Exclusion Criteria
Principal Investigator
Ossama Maher
More Information
To learn more visit: https://clinicaltrials.gov/study/NCT05566795.
This page was last updated on: August 06, 2025 08:52 AM